Clinical Trial Update: Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating acetyl-L-carnitine supplementation during hepatitis C therapy (pegylated interferon-α2b plus ribavirin) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Acetyl-L-carnitine (N-acetyl-L-carnitine)

Snippet

Sponsor: University of Catania | Conditions: Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis, Fatigue in Workers With Chronic C Hepatitis | Phase 4 | Status: COMPLETED